Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers

Aninye, Irene O.; Berry-Lawhorn, J. Michael; Blumenthal, Paul D.; Felder, Tamika; Jay, Naomi; Merrill, Janette K.; Messman, Jenna B; Nielsen, Sarah; Perkins, Rebecca B.; Rowen, Tami S.; Saslow, Debbie; Trimble, Connie; Smith‐McCune, Karen

doi:10.1089/jwh.2021.0507

Cited by 7 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were notable gaps indicating areas for targeted health messaging and counselling. [37,38] The significant positive correlation observed between the overall HPV-KS scores and the overall HBMS-HPVV scores indicates that higher levels of knowledge are associated with more favourable health beliefs regarding HPV infection and vaccination. This finding aligns with theoretical frameworks such as the Health Belief Model, which postulates that knowledge about a health threat influences one's beliefs and behaviours related to preventive actions.…”

Section: Discussionmentioning

confidence: 96%

HPV vaccine uptake, HPV infection and vaccination related knowledge and health beliefs among health sciences students in Coimbatore district, Tamil Nadu: An analytical cross-sectional study

Sanjay,

Narendranath,

Seetharaman

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Human Papillomavirus (HPV) infection, a prevalent sexually transmitted infection, is the leading cause of cervical cancer. However, it is preventable. Objectives:To determine the prevalence of HPV vaccine uptake among health sciences students in Coimbatore district, Tamil Nadu; and to determine the levels of knowledge and health beliefs regarding HPV infection and vaccination. Methods:This was an analytical cross-sectional study conducted among health sciences students in Coimbatore district, Tamil Nadu between November 2022, and January 2023. Results: A total of 1139 participants of mean (SD) age 19.5 years (1.5) were enrolled. More than two thirds were females (68.1%). The prevalence of HPV vaccine uptake was 5.0%; of which 87.6% were recommended by doctors. Of the 1082 participants who had not taken HPV vaccine, 35.8% were willing to take if provided free of cost. Only 4.8% participants had adequate overall knowledge regarding HPV infection and vaccination; with 9.8% having adequate general HPV knowledge, 29.3% having adequate HPV vaccine knowledge, 4.0% having adequate HPV testing, and 4.0% having adequate HPV vaccine availability knowledge. One in five (19.4%) participants had favourable/appropriate health beliefs regarding HPV infection and its vaccination – with 43.5% having perceived benefits, 39.5% having perceived sensitivity, 34.6% having perceived severity, and 19.8% having perceived obstacles. The overall HPV – Knowledge scale scores (HPV-KS) and overall HPV infection and vaccine health belief model scale (HBMS-HPVV) scores had a significant positive correlation (r=0.251; p=<0.001). Participants with employed mothers, from upper socioeconomic status, with history of HPV vaccination in the family, and uptake of HPV vaccine for self were associated with significantly higher overall HPV-KS scores. Similarly, overall HBMS-HPVV scores were significantly higher among participants from urban family residence, with literate mothers, and from upper socioeconomic status. Conclusion: The findings underscore the importance of multifaceted interventions that address knowledge gaps, dispel myths or misconceptions, and tailor messaging to resonate with diverse cultural and socioeconomic backgrounds.

show abstract

Section: Discussionmentioning

confidence: 96%

HPV vaccine uptake, HPV infection and vaccination related knowledge and health beliefs among health sciences students in Coimbatore district, Tamil Nadu: An analytical cross-sectional study

Sanjay,

Narendranath,

Seetharaman

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…There are currently no uniform indications for anal cancer screening or early diagnosis, although digital anal rectal examinations and high-resolution anoscopy can detect the early stages of the disease ( Nyitray et al ., 2020 ; Aninye et al ., 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Global trends in anal cancer incidence and mortality

Mignozzi,

Santucci,

Malvezzi

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective Anal cancer is a rare disease, affecting more frequently women than men, mainly related to human papillomavirus infection (HPV). Rising incidence and mortality have been reported over the past four decades in different countries. Methods To provide an up-to-date overview of recent trends in mortality from anal cancer, we analysed death certification data provided by the WHO in selected countries worldwide over the period from 1994 to 2020. We also analysed incidence derived from Cancer Incidence in Five Continents from 1990 to 2012 for all histologies as well as for anal squamous cell carcinoma (SCC). Results The highest age-standardised mortality rates around 2020 were registered in Central and Eastern Europe, such as Slovakia (0.9/100 000 men and 0.40/100 000 women), in the UK (0.24/100 000 men and 0.35/100 000 women), and Denmark (0.33/100 000 for both sexes), while the lowest ones were in the Philippines, Mexico, and Japan, with rates below 0.10/100 000 in both sexes. Upwards trends in mortality were reported in most countries for both sexes. Similarly, incidence patterns were upward or stable in most countries considered for both sexes. In 2008–2012, Germany showed the highest incidence rates (1.65/100 000 men and 2.16/100 000 women). Conclusion Attention towards vaccination against HPV, increased awareness of risk factors, mainly related to sexual behaviours and advancements in early diagnosis and management are required to control anal cancer incidence and mortality.

show abstract

“…In light of these results, it becomes important to stress HPV immunization as a public health priority and to identify organizational solutions capable of promoting adolescent-friendly prevention, vaccine confidence and a full recovery of coverage after the pandemic emergency [ 21 , 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost

et al. 2022

View full text Add to dashboard Cite

Objectives: Italy was the first European country to introduce universal vaccination of adolescents, for both males and females, against Human Papilloma Virus (HPV) starting in 2017 with the NIP 2017-2019’s release. However, vaccine coverage rates (VCRs) among adolescents have shown a precarious take-off since the NIP’s release, and this situation worsened due to the impact of the COVID-19 pandemic in 2020. The aim of this work is to estimate the epidemiological and economic impact of drops in VCRs due to the pandemic on those generations that missed the vaccination appointment and to discuss alternative scenarios in light of the national data. Methods: Through an analysis of the official ministerial HPV vaccination reports, a model was developed to estimate the number of 12-year-old males and females who were not vaccinated against HPV during the period 2017–2021. Based on previously published models that estimate the incidence and the economic impact of HPV-related diseases in Italy, a new model was developed to estimate the impact of the aggregated HPV VCRs achieved in Italy between 2017 and 2021. Results: Overall, in 2021, 723,375 girls and 1,011,906 boys born between 2005 and 2009 were not vaccinated against HPV in Italy (42% and 52% of these cohorts, respectively). As compared with the 95% target provided by the Italian NIP, between 505,000 and 634,000 girls will not be protected against a large number of HPV-related diseases. For boys, the number of the unvaccinated population compared to the applicable target is over 615,000 in the ‘best case scenario’ and over 749,000 in the ‘worst case scenario’. Overall, between 1.1 and 1.3 million young adolescents born between 2005 and 2009 will not be protected against HPV-related diseases over their lifetime with expected lifetime costs of non-vaccination that will be over EUR 905 million. If the 95% optimal VCRs were achieved, the model estimates a cost reduction equal to EUR 529 million, the net of the costs incurred to implement the vaccination program. Conclusion: Suboptimal vaccination coverage represents a missed opportunity, not only because of the increased burden of HPV-related diseases, but also in terms of economic loss. Thus, reaching national HPV immunization goals is a public health priority.

show abstract

Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers

Cited by 7 publications

References 56 publications

HPV vaccine uptake, HPV infection and vaccination related knowledge and health beliefs among health sciences students in Coimbatore district, Tamil Nadu: An analytical cross-sectional study

HPV vaccine uptake, HPV infection and vaccination related knowledge and health beliefs among health sciences students in Coimbatore district, Tamil Nadu: An analytical cross-sectional study

Global trends in anal cancer incidence and mortality

HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost

Contact Info

Product

Resources

About